Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Orbassano – page 12

215 clinical trials in Orbassano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Orbassano at a glance
215
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

215 trials in Orbassano

Open in trial search

Non-small cell lung cancer

Not recruiting

Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer metastatic

Not recruiting

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Inupadenant Hydrochloride
  • Sponsor:iTeos Belgium

Acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Metastatic renal cell carcinoma

Not recruiting

Study on Pembrolizumab for Patients with Resectable Metastases from Kidney Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Consorzio Oncotech

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088
  • Sponsor:Bayer AG

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Type 2 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Metformin Hydrochloride, Dapagliflozin, and Canagliflozin in Elderly Patients with Type 2 Diabetes

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Canagliflozin
  • Sponsor:Center For Outcomes Research And Clinical Epidemiology S.r.l.

Transitional cell carcinoma

Not recruiting

Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Orbassano

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer and mesothelioma treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Non-Small Cell Lung Cancer (NSCLC) Studies
  • Pleural Mesothelioma Treatments
  • Renal Cell Carcinoma Research

Multiple trials evaluating immunotherapy approaches and targeted molecular treatments for advanced stages of cancer.

02 Hematological Disorders

Research initiatives investigating treatments for blood disorders and related conditions, with particular focus on innovative therapies.

  • Sickle Cell Disease Management
  • Acute Myeloid Leukemia Treatments
  • Lymphoblastic Leukemia Studies

Studies examining new therapeutic approaches for blood disorders and their complications.

03 Cardiovascular Research

Clinical investigations focusing on heart failure prevention and innovative cardiovascular treatments.

  • Heart Failure Prevention Studies
  • Cardiovascular Risk Management
  • Novel Drug Combinations

Trials evaluating new therapeutic approaches for reducing cardiovascular events and improving patient outcomes.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.